Avanafil

Spedra

Bibliografia - Quali fonti bibliografiche per Avanafil?

1. Agenzia Italiana del Farmaco – AIFA, Spedra – Caratteristiche di Prodotto, 2016.


2. Alwaal A. et al., Drug Des. Devel. Ther., 2011, 5, 435.


3. Belkoff L.H. et al., Int. J. Clin. Pract., 2013, 67 (4), 333.


4. Burke R.M., Evans J.D., Vasc. Health Risk Manag., 2012, 8, 517.


5. Europenan Medicines Agency – EMA, Spedra – Product Information, 2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002581/human_med_001661.jsp&mid=WC0b01ac058001d124 (accesso: novembre 2017).


6. Food and Drug Administration – FDA, Postmarket Drug Safety Information for Patients and Providers, Questions and Answers about Viagra, Levitra, Cialis, and Revatio: Possible Sudden Hearing Loss, 2013, https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106525.htm (accesso: novembre 2017)


7. Goldenberg M.M., PT, 37 (6), 2012.


8. Goldstein I. et al., Mayo Clin. Proc., 2012, 87 (9), 843.


9. Goldstein I. et al., J. Sex Med., 2012a, 9 (4), 1122.


10. Hakky T.S., Jain L., Turk. J. Urol., 2015, 41 (2), 88.


11. Huang S.A., Lie J.D., PT, 2013, 38 (7), 407.


12. Jung J. et al., Clin. Ther., 2010, 32 (6), 1178.


13. Katz E.G. et al., Ther. Clin. Risk Manag., 2014, 10, 701.


14. Limin M. et al., Expert Opin. Investig. Drugs, 2010, 19 (11), 1427.


15. Mulhall J.P. et al., J. Urol., 2013, 189 (6), 2229.


16. Nehra A. et al., Eur. Urol., 2006, 5 (2), 138.


17. Swearingen D. et al., Drugs Context., 2013, Feb 26;2013:212248. doi: 10.7573/dic.212248.